News - Celgene

Filter

Current filters:

Celgene

Popular Filters

26 to 50 of 91 results

Celgene's pomalidomide meets primary endpoint in multiple myeloma

05-09-2013

US biotech major Celgene (Nasdaq: CELG) announced that positive updated results from MM-003, a Phase…

BiotechnologyCelgeneImnovidOncologypomalidomidePomalystResearch

Adimab enters collaborations with Celgene and Innovent; gets milestones

21-08-2013

USA-based therapeutic antibody developer Adimab this week announced two new collaborations, one with…

AdimabBiotechnologyCelgeneInnovent BiologicsLicensingResearch

Epizyme's leukemia compound granted orphan drug designation

19-08-2013

US biotech company Epizyme (NASDAQ: EPZM) has been granted orphan drug designation for its experimental…

BiotechnologyCelgeneEpizymeNorth AmericaOncologyRegulation

MorphoSys closes on the alliance with Celgene

14-08-2013

German biotech firm MorphoSys (FSE: MOR) that its MOR202 alliance with Celgene (Nasdaq: CELG), the world's…

BiotechnologyCelgeneFinancialLicensingMOR202MorphoSysOncology

Pomalidomide Celgene OKed in Europe

09-08-2013

The European Commission has granted approval for US biotech firm Celgene's (Nasdaq: CELG) Pomalidomide…

BiotechnologyCelgeneEuropeImnovidOncologypomalidomidePomalidomide CelgeneRegulation

Three-year survival improves in SMM patients treated with Revlimid, study shows

02-08-2013

US biotech firm Celgene (Nasdaq: CELG) has released positive new data evaluating treatment with Revlimid…

CelgeneNorth AmericaOncologyPharmaceuticalResearchRevlimid

Array BioPharma signs up to $387 million deal

30-07-2013

In a second licensing deal this week US biotech major Celgene (Nasdaq: CELG) has entered into a strategic…

Array BioPharmaBiotechnologyCelgeneInflammatory diseasesLicensing

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Celgene's 2nd-qtr results and forecasts beat expectations

25-07-2013

Shares of US biotech Celgene (Nasdaq: CELG) rose 1.6% in pre-market trading this morning (July 25), as…

BiotechnologyCelgeneFinancial

Celgene halts blood cancer drug trial

19-07-2013

US biotech major Celgene Corp (Nasdaq: CELG) said yesterday (July 18) that, after consultation with the…

BiotechnologyCelgeneOncologyResearchRevlimid

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM

11-07-2013

US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

Tengion closes deals to advance organ regeneration platform

09-07-2013

USA-based Tengion (OTCQB: TNGN), a leader in regenerative medicine, says it has now closed transactions…

BiotechnologyCelgeneFinancialLicensingResearchTengion

Onyx Pharma rejects Amgen's unsolicited $120 per share takeover offer

01-07-2013

Following a day of speculation and rumor on Friday, US biotech firm Onyx Pharmaceuticals (Nasdaq: ONXX)…

AmgenBayerBiotechnologyCelgeneMergers & AcquisitionsOncologyOnyx PharmaceuticalsPfizerRoche

MorphoSys and Celgene in deal to advance MOR202 for multiple myeloma

27-06-2013

German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world's largest independent…

BiotechnologyCelgeneEuropeLicensingMergers & AcquisitionsMOR202MorphoSysOncology

Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid

14-06-2013

Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the…

Anti-viralsBionor PharmaCelgenePharmaceuticalResearchRevlimidVacc-4xVaccines

US FDA backs new indication for Celgene's Revlimid

06-06-2013

The US Food and Drug Administration has approved US biotech firm Celgene's (Nasdaq: CELG) supplemental…

BiotechnologyCelgeneNorth AmericaOncologyRegulationRevlimid

Latest news from ASCO: Celgene's Revlimid; AbbVie's ABT-199; DelMar's VAL-083

04-06-2013

Continuing our coverage of the ongoing American Society of Clinical Oncology (ASCO) meeting in Chicago,…

AbbVieABT-199CelgeneDelMar PharmaceuticalsOncologyPharmaceuticalResearchRevlimidVAL-083

Concert Pharma in $300 million-plus deal with Celgene

07-05-2013

Privately-held biotech firm Concert Pharmaceuticals said yesterday (May 6) that it has entered into a…

Anti-Arthritics/RheumaticsapremilastBiotechnologyCelgeneConcert PharmaceuticalsInflammatory diseasesLicensingOncologyResearch

Celgene partners with FORMA Thera on drugs targeting protein homeostasis

30-04-2013

Privately-held FORMA Therapeutics has entered into a strategic collaboration agreement with US biotech…

BiotechnologyCelgeneFORMA TherapeuticsLicensingNeurologicalOncologyResearch

Celgene 1st-qtr revenues leap 15% but profit falls 4%

28-04-2013

US biotech firm Celgene (Nasdaq: CELG) last week posted first-quarter 2013 financial results, showing…

BiotechnologyCelgeneFinancial

Cyclacel sells four disputed romidepsin-related patents to Celgene

05-04-2013

USA based Cyclacel Pharmaceuticals (Nasdaq: CYCC) says that it has entered into a definitive agreement…

BiotechnologyCelgeneCyclacel PharmaceuticalsLegalOncologyPatentsromidepsin

26 to 50 of 91 results

Back to top